Market News AIOpen the app

Truist Securities changed its rating for Evolent Health to Buy and set a $6 price target.

OpinionRead the original at marketscreener.com
Good for EVH

Truist moved Evolent's rating from Hold to Buy, a favorable sign. It kept its $6-per-share target unchanged, which tempers the upgrade.

EVH · Evolent Health, Inc.

AI read · Good for EVH

The AI's read

The upgrade reflects a more favorable view of Evolent's shares. The unchanged target tempers that message, but the rating change is still the clearest new company-specific signal.

Get alerts for EVH

Follow Evolent Health, Inc. (EVH) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EVH
Free on the App Store and Google Play, or on the web.